Vytorin Beats Lipitor At LDL-Lowering In Data Analysis

A Merck/Schering-Plough-sponsored data analysis presented at the American College of Cardiology Scientific Sessions March 13 showed that more patients treated with Vytorin (ezetimibe/simvastatin) achieved lower levels of LDL cholesterol and apolipoprotein B compared to patients taking Pfizer's Lipitor (atorvastatin)